- Home
- PANW vs AZN Comparison
PANW vs AZN Comparison
Compare PANW & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | AZN |
|---|---|---|
| Founded | 2005 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.4B | 316.4B |
| IPO Year | 2012 | 1995 |
Fundamental Metrics
Financial Performance| Metric | PANW | AZN |
|---|---|---|
| Price | $339.74 | $169.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 39 | 1 |
| Target Price | ★ $216.28 | N/A |
| AVG Volume (30 Days) | ★ 5.3M | 4.1M |
| Earning Date | 05-19-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.79 | N/A |
| Revenue | ★ $2,273,100,000.00 | N/A |
| Revenue This Year | $24.93 | $10.34 |
| Revenue Next Year | $19.97 | $6.43 |
| P/E Ratio | $444.20 | ★ $31.91 |
| Revenue Growth | ★ 29.04 | N/A |
| 52 Week Low | $139.57 | $72.90 |
| 52 Week High | $398.88 | $212.71 |
Technical Indicators
Market Signals| Indicator | PANW | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 48.15 | 53.08 |
| Support Level | $311.75 | $164.06 |
| Resistance Level | $368.49 | $175.04 |
| Average True Range (ATR) | 13.83 | 2.51 |
| MACD | -4.77 | 1.54 |
| Stochastic Oscillator | 12.90 | 96.89 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three-fourths of the Global 2000.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.